自我引导数字行为疗法与主动对照治疗纤维肌痛(PROSPER-FM):一项3期、多中心、随机对照试验
PROSPER-FM试验在美国25个社区站点纳入275例成人纤维肌痛患者,1:1随机分入数字接纳承诺疗法(ACT)组或主动对照组。第12周时,ACT组140例中99例(71%)报告患者总体印象变化(PGIC)改善,对照组135例中30例(22%)改善,差异为48.4%(95%CI 37.9-58.9;p<0.0001),未报告器械相关安全事件。
要点
- 数字ACT组第12周PGIC应答率71%(99/140),主动对照组为22%(30/135)。
- 两组应答率差异为48.4%(95%CI 37.9-58.9;p<0.0001)。
- 未报告器械相关安全事件。
核心结论
- 在成人纤维肌痛管理中,与数字症状追踪相比,数字ACT安全且有效。
研究设计与样本
- PROSPER-FM为3期、多中心、随机对照试验,在美国25个社区站点开展,纳入22-75岁成人纤维肌痛患者。
- 参与者按1:1随机分入12周自我引导智能手机数字ACT组或主动对照组,主动对照组提供每日症状追踪监测及健康与纤维肌痛相关教育材料。
- 随机化采用基于网络的系统,在站点层面按四例区组进行;分析采用意向性治疗原则;试验注册号NCT05243511。
主要发现
- 2022年2月8日至2023年2月2日筛查590人,275人(257名女性、18名男性)被随机分配至数字ACT组(n=140)和主动对照组(n=135)。
- 第12周时,数字ACT组140例中99例(71%)报告PGIC改善,主动对照组135例中30例(22%)报告改善。
- 两组改善比例差异为48.4%(95%CI 37.9-58.9;p<0.0001)。
- 未报告器械相关安全事件。
关键数值与推荐
- 主要终点为第12周患者总体印象变化(PGIC)应答率。
- 数字ACT组PGIC应答率为71%(99/140),主动对照组为22%(30/135)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: International guidelines have recommended cognitive behavioural therapy, including acceptance and commitment therapy (ACT), as it offers validated benefits for managing fibromyalgia; however, it is inaccessible to most patients. We aimed to evaluate the effect of a 12-week, self-guided, smartphone-delivered digital ACT programme on fibromyalgia management. METHODS: In the PROSPER-FM randomised clinical trial conducted at 25 US community sites, adult participants aged 22-75 years with fibromyalgia were recruited and randomly assigned (1:1) to the digital ACT group or an active control group that offered daily symptom tracking and monitoring and access to health-related and fibromyalgia-related educational materials. Randomisation was done with a web-based system in permuted blocks of four at the site level. We used a blind-to-hypothesis approach in which participants were informed they would be randomly assigned to one of two potentially effective therapies under evaluation. Research staff were not masked to group allocation, with the exception of a masked statistics group while preparing statistical programming for the interim analysis. The primary endpoint was patient global impression of change (PGIC) response rate at week 12. Analyses were by intention to treat. The trial was registered with ClinicalTrials.gov, NCT05243511 (now fully closed). FINDINGS: Between Feb 8, 2022, and Feb 2, 2023, 590 individuals were screened, of whom 275 (257 women and 18 men) were randomly assigned to the digital ACT group (n=140) and the active control group (n=135). At 12 weeks, 99 (71%) of 140 ACT participants reported improvement on PGIC versus 30 (22%) of 135 active control participants, corresponding to a difference in proportions of 48·4% (95% CI 37·9-58·9; p<0·0001). No device-related safety events were reported. INTERPRETATION: Digital ACT was safe and efficacious compared with digital symptom tracking in managing fibromyalgia in adult patients. FUNDING: Swing Therapeutics.
引用
- Gendreau RM, McCracken LM, Williams DA, et al. Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3, multicentre, randomised controlled trial. Lancet. 2024. PMID: 38991582. doi:10.1016/S0140-6736(24)00909-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。